Cis-imidazolines

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C548S311100

Reexamination Certificate

active

07579368

ABSTRACT:
There are presented compounds of the formulaor pharmaceutically acceptable salts thereof,wherein Y1, Y2, X1, X2, X3and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity.

REFERENCES:
patent: 6734302 (2004-05-01), Kong et al.
patent: 7425638 (2008-09-01), Haley et al.
patent: WO 03/051359 (2003-06-01), None
patent: WO 03/051359 (2003-06-01), None
patent: WO 2005/110996 (2005-11-01), None
patent: WO 2005/123691 (2005-12-01), None
Vassilev, et. al., Science, V.303, N.5659, p. 844-848 (2004).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Cis-imidazolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cis-imidazolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cis-imidazolines will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4053807

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.